Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes

Rhea-AI Filing Summary

Intellia Therapeutics EVP and Chief Technical Officer Eliana Clark reported a mix of equity awards and a small tax-related sale. Clark received 7,353 shares of common stock from a grant of restricted stock units and a stock option for 10,505 shares. On a separate date, 607 shares were automatically sold at $13.78 per share to cover tax withholding obligations, leaving 93,864 common shares held directly afterward.

Insider Trade Summary

Net Seller: 607 shares ($8,364)

Net Sell 3 txns

Insider Clark Eliana

Role EVP, Chief Technical Officer

Sold 607 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	607	$13.78	$8K
Grant/Award	Stock Option (right to buy)	10,505	$0.00	--
Grant/Award	Common Stock	7,353	$0.00	--

Holdings After Transaction: Common Stock — 93,864 shares (Direct); Stock Option (right to buy) — 10,505 shares (Direct)

Footnotes (1)

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark Eliana

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		7,353	A	$0	94,471	D
Common Stock	03/02/2026		S(2)		607	D	$13.78	93,864	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.78	03/01/2026		A		10,505		(3)	02/29/2036	Common Stock	10,505	$0	10,505	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.

3. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	James Basta, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NTLA executive Eliana Clark report on this Form 4?

Eliana Clark reported receiving 7,353 shares of Intellia common stock from a restricted stock unit grant and a stock option for 10,505 shares. She also reported an automatic sale of 607 shares to cover tax withholding obligations.

How many Intellia (NTLA) shares did Eliana Clark sell, and at what price?

Eliana Clark reported the sale of 607 shares of Intellia common stock at $13.78 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax withholding on vested restricted stock units, not a discretionary open-market trade.

What new equity awards did Eliana Clark receive from Intellia Therapeutics (NTLA)?

Eliana Clark received a grant of 7,353 shares of common stock based on restricted stock units and a stock option covering 10,505 shares of common stock. The stock option was granted at no cost per option share on the grant date disclosed.

How does the Form 4 describe the vesting schedule of Eliana Clark’s new stock option at NTLA?

The stock option granted on March 1, 2026 covers shares of common stock, with 33% vesting on January 1, 2027. The remaining 67% vests in 24 substantially equal monthly installments after that initial vesting date, according to the filing footnote.

Was Eliana Clark’s sale of Intellia (NTLA) shares a voluntary open-market transaction?

The filing explains the 607-share sale was a mandatory sell-to-cover transaction. It was executed to satisfy tax withholding obligations upon the vesting of restricted stock units and is explicitly described as not being a volitional trade by the reporting person.

How many Intellia (NTLA) common shares did Eliana Clark hold directly after these transactions?

After the reported transactions, Eliana Clark directly held 93,864 shares of Intellia common stock. This figure reflects her ownership following the 7,353-share award and the 607-share automatic tax-related sale described in the Form 4.